Brainsway Ltd. (BWAY)

NASDAQ: BWAY · IEX Real-Time Price · USD
6.65
0.15 (2.31%)
May 18, 2022 12:43 PM EDT - Market open
Market Cap114.62M
Revenue (ttm)31.51M
Net Income (ttm)-7.08M
Shares Out17.24M
EPS (ttm)-0.41
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume671
Open6.41
Previous Close6.50
Day's Range6.41 - 6.65
52-Week Range5.03 - 11.77
Beta0.68
AnalystsBuy
Price Target0.10 (-98.5%)
Earnings DateMay 11, 2022

About BWAY

Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company prim...

IndustryHealth Care Equipment & Supplies
IPO DateApr 17, 2019
Employees118
Stock ExchangeNASDAQ
Ticker SymbolBWAY
Full Company Profile

Financial Performance

In 2021, Brainsway's revenue was $29.66 million, an increase of 34.46% compared to the previous year's $22.06 million. Losses were -$6.46 million, 20.0% more than in 2020.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for BWAY stock is "Buy." The 12-month stock price forecast is 0.1, which is a decrease of -98.50% from the latest price.

Price Target
$0.1
(-98.50% downside)
Analyst Consensus: Buy
Stock Forecasts

News

BrainsWay Reports First Quarter 2022 Financial Results and Operational Highlights

Revenue Growth of 30% Year-over-Year in Q1 2022

1 week ago - GlobeNewsWire

BrainsWay Launches #DontMissAnotherMoment Social Media Campaign to Promote Mental Health Awareness Month

BrainsWay will donate $5 per share, $2 per comment, and $1 per like to support the work of Mental Health America BrainsWay will donate $5 per share, $2 per comment, and $1 per like to support the work o...

2 weeks ago - GlobeNewsWire

BrainsWay to Report First Quarter Financial Results on May 11, 2022

BURLINGTON, Mass. and JERUSALEM, April 27, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatmen...

3 weeks ago - GlobeNewsWire

BrainsWay Appoints Dr. Joachim Seidel as Vice President of Corporate Development and Strategy

Dr. Seidel has more than 20 years of experience in the medical device industry Dr. Seidel has more than 20 years of experience in the medical device industry

1 month ago - GlobeNewsWire

BrainsWay Reports Fourth Quarter and Full-Year 2021 Financial Results and Operational Highlights

Revenue Growth of 34% in 2021, with Record Quarterly and Annual Revenues

2 months ago - GlobeNewsWire

BrainsWay to Present at the 32nd Annual Oppenheimer Healthcare Conference

BURLINGTON, Mass. and JERUSALEM, March 01, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatmen...

2 months ago - GlobeNewsWire

BrainsWay to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

BURLINGTON, Mass. and JERUSALEM, Feb. 01, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatment...

3 months ago - GlobeNewsWire

BrainsWay Announces Final Local Coverage Determination Issued by Regional Medicare Administrative Contractor Palmetto...

Palmetto GBA Covers Medicare Patients in Seven States Palmetto GBA Covers Medicare Patients in Seven States

3 months ago - GlobeNewsWire

BrainsWay Announces Addition of Markus Heilig, M.D., Ph.D., to Scientific Advisory Board

World-Renowned Specialist in Addiction and Anxiety Treatment Joins Premier Group of Researchers and Clinicians Advising Company World-Renowned Specialist in Addiction and Anxiety Treatment Joins Premier...

3 months ago - GlobeNewsWire

BrainsWay Announces Multiple Publications of New Real-World OCD Data for its Deep TMS™ System

Positive Data Support the Durability and Cost-Effectiveness of Deep TMS as a Treatment for Obsessive-Compulsive Disorder Positive Data Support the Durability and Cost-Effectiveness of Deep TMS as a Trea...

4 months ago - GlobeNewsWire

BrainsWay Announces Publication of Deep TMS™ Trial Results for Reduction of Heavy Drinking in Alcohol-Dependent Subjects

Randomized, Placebo-Controlled, Double-Blind Pilot Study Evaluated Deep TMS Treatment in Reducing Alcohol Consumption and Craving for Adults with Alcohol Use Disorder

5 months ago - GlobeNewsWire

BrainsWay Reports Third Quarter 2021 Financial Results and Operational Highlights

Revenue Growth of 34% Year-over-Year in Q3 2021

6 months ago - GlobeNewsWire

BrainsWay to Report Third Quarter 2021 Financial Results on November 17, 2021

BURLINGTON, Mass. and JERUSALEM, Nov. 03, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatment...

6 months ago - GlobeNewsWire

BrainsWay Announces Data Published in World Psychiatry on Deep Transcranial Magnetic Stimulation (Deep TMS™) for Smok...

Evidence Supports Use of Deep TMS as a Safe and Effective Treatment for Smoking Addiction

7 months ago - GlobeNewsWire

BrainsWay to Participate in Two Upcoming Investor Conferences

BURLINGTON, Mass. and JERUSALEM, Sept. 09, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatmen...

8 months ago - GlobeNewsWire

BrainsWay to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

BURLINGTON, Mass. and JERUSALEM, Aug. 30, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatment...

8 months ago - GlobeNewsWire

BrainsWay Stock Gains On FDA Expanded Use Approval For Its Stimulation Device

The FDA has cleared BrainsWay Ltd's (NASDAQ:BWAY) Deep Transcranial Magnetic Stimulation (Deep TMS) System to reduce comorbid anxiety symptoms in adult patients with depression, also known as anxious de...

9 months ago - Benzinga

FDA Clears BrainsWay Deep TMS™ System for Decreasing Anxiety Symptoms in Depressed Patients

Expanded Depression Indication Further Demonstrates Company's Leadership Position Expanded Depression Indication Further Demonstrates Company's Leadership Position

9 months ago - GlobeNewsWire

BrainsWay Hosting Key Opinion Leader Webinar on its Deep TMS™ Therapy for Treating Mental Health Disorders

BURLINGTON, Mass. and JERUSALEM, Aug. 17, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatment...

9 months ago - GlobeNewsWire

BrainsWay Reports Second Quarter 2021 Financial Results and Operational Highlights

Strong Revenue Growth of 45% Year-over-Year in Q2 2021

9 months ago - GlobeNewsWire

BrainsWay to Report Second Quarter 2021 Financial Results on August 11, 2021

CRESSKILL, N.J. and JERUSALEM, July 28, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments ...

9 months ago - GlobeNewsWire

MindPath Care Centers Hosts Open House in Charlotte to Introduce FDA-Cleared Deep TMS™ Treatment for Major Depressive...

Engaging event for local mental health clinicians to learn more about BrainsWay's Deep Transcranial Magnetic Stimulation (Deep TMS) helmet, cleared to treat MDD and OCD, currently available in Charlotte.

10 months ago - GlobeNewsWire

BrainsWay to Present at Clinical TMS Society Annual Meeting and Psych Congress Elevate

CRESSKILL, N.J. and JERUSALEM, Israel, June 07, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd . (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation tr...

11 months ago - GlobeNewsWire

BrainsWay (BWAY) is in Overbought Territory: What's Next?

BrainsWay (BWAY) has moved higher as of late, but there could definitely be trouble on the horizon for this company

11 months ago - Zacks Investment Research

Brainsway Ltd. Sponsored ADR (BWAY) Moves 10.6% Higher: Will This Strength Last?

Brainsway Ltd. Sponsored ADR (BWAY) saw its shares surge in the last session with trading volume being higher than average.

11 months ago - Zacks Investment Research